Cytology and Biomarkers in NMIBC
Cystoscopy and cytology remain the standard for diagnosis, but a plethora of urinary biomarkers could someday be a useful adjunct to NMIBC surveillance.
Bladder Cancer
FEATURES
Latest Bladder Cancer News
Bladder Cancer Surgery Safe Following Neoadjuvant Immunotherapy
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Adding Chemo to Radiation Treatment for MIBC Does Not Worsen HRQoL
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
Investigational Drug for Non-Muscle Invasive Bladder Cancer Gets Breakthrough Status
N-803 is an IL-15 superagonist complex consisting of an IL-15 mutant bound to an IL-15 receptor α/IgG1 Fc fusion protein
FDA Approves Therapy for Advanced Urothelial Cancer
Padcev is the first antibody-drug conjugate approved for advanced urothelial cancer patients.
Novel Gene Therapy Shows Efficacy in BCG-Refractory High-Grade NMIBC
Nadofaragene firadenovec, an adenovirus vector-based gene therapy containing the gene interferon alfa-2b, achieved a complete response in 53% of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease at 3 months.
Risk Factors for Reoperation After Radical Cystectomy Identified
Higher body mass index, a history of chronic obstructive pulmonary diseases, and black race are associated with an increased risk of reoperation within 30 days of racial cystectomy, a study found.
Tools for Assessing, Managing Elderly With Cancer for Malnutrition
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
Radical Cystectomy Approaches Offer Similar Long-Term Oncologic Outcomes
Laparoscopic, robotic-assisted, and open radical cystectomy are associated with similar long-term oncologic outcomes among patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer, according to findings from the CORAL study, the only randomized trial comparing the 3 surgical approaches. In the study, investigators randomly assigned patients with muscle-invasive bladder cancer (MIBC, 38 patients) or high-risk non-muscle…
FDA Labeling Restriction Quickly Reflected in Oncology Practice
FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
